Recent clinical evidence on metronomic dosing in controlled clinical trials : a systematic literature review
Publiceringsår
2020
Upphovspersoner
Wichmann, Viktor; Eigeliene, Natalja; Saarenheimo, Jatta; Jekunen, Antti
Abstrakt
Introduction: Metronomic dosing is used to give continuous chemotherapy at low doses. The low doses have minimal side effects and may enable cancer treatment to be remodeled toward the management of chronic disease. Methods: We searched PubMed database to obtain relevant clinical trials studying metronomic chemotherapy (MCT). Our main focus was to find controlled phase II and phase III trials. Results: This systematic review summarizes the results of 91 clinical reports focusing on randomized phase II and phase III clinical studies between 2012 and 2018. During that time, nine randomized phase II and 10 randomized phase III studies were published. In the majority of the studies, MCT was well tolerated, and major side effects were rarely seen. Altogether, 4 phase III studies and 4 randomized phase II studies presented positive results and some clinical benefit. Discussion: Most of the studies did not show significantly improved overall survival or progression-free survival. Typically, the metronomic dosing was explored in a maintenance setup and was added to other agents given within normal high doses, whereas no trial was performed challenging metronomic dosing and best supportive care in later treatment lines. Therefore, there is no definite evidence on the efficacy of single metronomic dosing and firm evidence of metronomic dosing is still missing. There is a need for further confirmation of the usefulness of this approach in clinical practice.
Visa merOrganisationer och upphovspersoner
Åbo universitet
Jekunen Antti
Åbo universitetscentralsjukhus specialupptagningsområde
Jekunen Antti
Saarenheimo Jatta
Eigeliene Natalija
Wichmann Viktor
Publikationstyp
Publikationsform
Artikel
Moderpublikationens typ
Tidning
Artikelstyp
En översiktsartikel
Målgrupp
VetenskapligKollegialt utvärderad
Kollegialt utvärderadUKM:s publikationstyp
A2 Översiktsartikel i en vetenskaplig tidskriftPublikationskanalens uppgifter
Journal
Förläggare
Volym
59
Nummer
7
Sidor
775-785
ISSN
Publikationsforum
Publikationsforumsnivå
1
Öppen tillgång
Öppen tillgänglighet i förläggarens tjänst
Nej
Parallellsparad
Nej
Övriga uppgifter
Vetenskapsområden
Cancersjukdomar; Farmaci
Nyckelord
[object Object],[object Object],[object Object],[object Object]
Publiceringsland
Förenade kungariket
Förlagets internationalitet
Internationell
Språk
engelska
Internationell sampublikation
Nej
Sampublikation med ett företag
Nej
DOI
10.1080/0284186X.2020.1744719
Publikationen ingår i undervisnings- och kulturministeriets datainsamling
Ja